Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 17Terminated 7Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Neoplasm, Residual 1Lymphoma, Primary Effusion 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Leukemia, Hairy Cell 1Leukemia 1

Interventions

pembrolizumab 84Specimen Handling 79Carboplatin 74Magnetic Resonance Spectroscopy 71Biopsy 58Nivolumab 55Cisplatin 55Paclitaxel 46Cyclophosphamide 44durvalumab 37Radiotherapy 36Radiation 35Rituximab 34olaparib 33Etoposide 33Dexamethasone 33Ipilimumab 30Gemcitabine 30Lenalidomide 28Taxes 27Pemetrexed 27Doxorubicin 27Docetaxel 27Bevacizumab 24Prednisone 23Cytarabine 23X-Rays 22Trastuzumab 21cabozantinib 20Disulfides 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Has results × Electrocardiography × Clear all
NCT03789240 2026-03-03

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
33 enrolled 17 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡